IceCure's Promising 5-Year Study Results for Kidney Cancer Cryoablation Show High Recurrence-Free Rates IceCure Medical has revealed impressive five-year results from its ICESECRET study, highlighting significant recurrence-free rates for kidney cancer treatment, promoting its minimally invasive ProSense® technology.

IceCure's Promising 5-Year Study Results for Kidney Cancer Cryoablation Show High Recurrence-Free Rates #Israel #Caesarea #IceCure_Medical #Cryoablation #ProSense

IceCure Medical Welcomes Meir Peleg as Chief Financial Officer to Drive Growth IceCure Medical has appointed Meir Peleg as its CFO, bringing years of financial expertise to aid in the company's strategic growth in cryoablation technology.

IceCure Medical Welcomes Meir Peleg as Chief Financial Officer to Drive Growth #Israel #Caesarea #IceCure_Medical #ProSense #Meir_Peleg

IceCure Medical's ProSense® Cryoablation Gains FDA Approval for Breast Cancer Study The FDA has approved IceCure Medical's ProSense® cryoablation system for a post-marketing study in low-risk breast cancer treatment, engaging major U.S. medical institutions.

IceCure Medical's ProSense® Cryoablation Gains FDA Approval for Breast Cancer Study #United_States #Caesarea #IceCure_Medical #Cryoablation #ProSense

IceCure Medical's ProSense Cryoablation: A Game-Changer for Breast Fibroadenoma Treatment IceCure Medical's recent study reveals the effectiveness of ProSense® cryoablation for treating breast fibroadenomas, fostering potential shifts in clinical guidelines.

IceCure Medical's ProSense Cryoablation: A Game-Changer for Breast Fibroadenoma Treatment #Israel #Caesarea #IceCure_Medical #Cryoablation #ProSense

IceCure Medical Marks Milestone in Kidney Cancer Cryoablation Study with 5-Year Follow-Up Outcomes IceCure Medical has completed a significant 5-year follow-up in its ICESECRET kidney cancer cryoablation study. Final analysis is anticipated by Q2 2026.

IceCure Medical Marks Milestone in Kidney Cancer Cryoablation Study with 5-Year Follow-Up Outcomes #Israel #Caesarea #IceCure_Medical #ProSense #Kidney_Cancer

IceCure Medical Announces CFO Departure After Key Achievements in Nine Years IceCure Medical has announced the departure of CFO Ronen Tsimerman after nearly a decade, highlighting significant milestones achieved during his tenure.

IceCure Medical Announces CFO Departure After Key Achievements in Nine Years #Israel #Caesarea #IceCure_Medical #Cryoablation #ProSense